Atractylenolide III activates the hepatic adiponectin receptor 1 (AdipoR1)/AMPK axis to ameliorate non-alcoholic fatty liver disease [28]. The gene discussed is ADIPOR1; the disease is metabolic dysfunction-associated steatotic liver disease.